Vivos Therapeutics Retained Earnings (Accumulated Deficit) 2020-2024 | VVOS

Vivos Therapeutics retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Vivos Therapeutics Retained Earnings (Accumulated Deficit) 2020-2024 | VVOS

Vivos Therapeutics retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.2B
Takeda Pharmaceutical (TAK)$43.3B
Sandoz Group AG (SDZNY)$19.5B
Merck (MKKGY)$19.2B
Astellas Pharma (ALPMY)$18.2B
United Therapeutics (UTHR)$16.1B
Summit Therapeutics (SMMT)$14.7B
Neurocrine Biosciences (NBIX)$12.1B
Shionogi (SGIOY)$11.9B
Catalent (CTLT)$10.7B
Jazz Pharmaceuticals (JAZZ)$7.1B
Madrigal Pharmaceuticals (MDGL)$6.9B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$5.7B
Ionis Pharmaceuticals (IONS)$5.3B
Crinetics Pharmaceuticals (CRNX)$5.1B
PTC Therapeutics (PTCT)$3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2.2B
Centessa Pharmaceuticals (CNTA)$1.9B
Evotec AG (EVO)$1.8B
Recursion Pharmaceuticals (RXRX)$1.8B
Xencor (XNCR)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.5B
Indivior (INDV)$1.4B
Harrow (HROW)$1.4B